| Title | Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment. | | Author(s) | Mease PJ | | Institution | Seattle Rheumatology Associates, Seattle, Washington 98104, USA. pmease@nwlink.com | | Source | Curr Opin Rheumatol 2003 May; 15(3):205-12. | | MeSH | Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Arthritis, Psoriatic
Arthritis, Reactive
Chronic Disease
Clinical Trials
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Severity of Illness Index
Spondylarthropathies
Spondylitis, Ankylosing
Treatment Outcome
| | Abstract | The inflammatory arthritides included in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, undifferentiated spondyloarthropathy, and arthritis associated with inflammatory bowel disease) may cause significant, progressive morbidity. Therapy with nonsteroidal antiinflammatory drugs and traditionally used disease-modifying antirheumatic drugs, such as methotrexate, often fails in patients with more severe peripheral arthropathy and axial involvement, and alternative treatment options have been limited. With increased understanding of the pathologic processes involved in these disorders, new therapeutics have arisen and are being investigated in the various subtypes of spondyloarthropathy. This article reviews recent progress in disease-modifying therapy for spondyloarthropathy, including new biologic response modifiers, such as the tumor necrosis factor-alpha inhibitors etanercept and infliximab. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 12707572 |
|
